{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:18:27Z","timestamp":1792685907888,"version":"4.5.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,1,9]],"date-time":"2016-01-09T00:00:00Z","timestamp":1452297600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Amino Acids"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s00726-015-2165-0","type":"journal-article","created":{"date-parts":[[2016,1,9]],"date-time":"2016-01-09T05:53:01Z","timestamp":1452318781000},"page":"1929-1940","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["Creatine for neuroprotection in neurodegenerative disease: end of story?"],"prefix":"10.1007","volume":"48","author":[{"given":"Andreas","family":"Bender","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Klopstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,9]]},"reference":[{"issue":"15","key":"2165_CR1","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1212\/01.wnl.0000277645.60799.0e","volume":"69","author":"JE Ahlskog","year":"2007","unstructured":"Ahlskog JE (2007) I can\u2019t get no satisfaction: still no neuroprotection for Parkinson disease. Neurology 69(15):1476\u20131477. doi: 10.1212\/01.wnl.0000277645.60799.0e","journal-title":"Neurology"},{"issue":"4","key":"2165_CR2","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.pbb.2012.03.005","volume":"101","author":"PJ Allen","year":"2012","unstructured":"Allen PJ, D\u2019Anci KE, Kanarek RB, Renshaw PF (2012) Sex-specific antidepressant effects of dietary creatine with and without sub-acute fluoxetine in rats. Pharmacol Biochem Behav 101(4):588\u2013601. doi: 10.1016\/j.pbb.2012.03.005","journal-title":"Pharmacol Biochem Behav"},{"issue":"3","key":"2165_CR3","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1006\/nbdi.2001.0406","volume":"8","author":"OA Andreassen","year":"2001","unstructured":"Andreassen OA, Dedeoglu A, Ferrante RJ, Jenkins BG, Ferrante KL, Thomas M, Friedlich A, Browne SE, Schilling G, Borchelt DR, Hersch SM, Ross CA, Beal MF (2001a) Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington\u2019s disease. Neurobiol Dis 8(3):479\u2013491","journal-title":"Neurobiol Dis"},{"issue":"2","key":"2165_CR4","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1046\/j.1471-4159.2001.00188.x","volume":"77","author":"OA Andreassen","year":"2001","unstructured":"Andreassen OA, Jenkins BG, Dedeoglu A, Ferrante KL, Bogdanov MB, Kaddurah-Daouk R, Beal MF (2001b) Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. J Neurochem 77(2):383\u2013390","journal-title":"J Neurochem"},{"issue":"4","key":"2165_CR5","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.brainresbull.2008.02.035","volume":"76","author":"RH Andres","year":"2008","unstructured":"Andres RH, Ducray AD, Schlattner U, Wallimann T, Widmer HR (2008) Functions and effects of creatine in the central nervous system. Brain Res Bull 76(4):329\u2013343. doi: 10.1016\/j.brainresbull.2008.02.035","journal-title":"Brain Res Bull"},{"issue":"6","key":"2165_CR6","doi-asserted-by":"publisher","first-page":"508","DOI":"10.3109\/17482961003797130","volume":"11","author":"N Atassi","year":"2010","unstructured":"Atassi N, Ratai EM, Greenblatt DJ, Pulley D, Zhao Y, Bombardier J, Wallace S, Eckenrode J, Cudkowicz M, Dibernardo A (2010) A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 11(6):508\u2013513. doi: 10.3109\/17482961003797130","journal-title":"Amyotroph Lateral Scler"},{"issue":"1\u20133","key":"2165_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00726-001-0133-3","volume":"23","author":"M Balestrino","year":"2002","unstructured":"Balestrino M, Lensman M, Parodi M, Perasso L, Rebaudo R, Melani R, Polenov S, Cupello A (2002) Role of creatine and phosphocreatine in neuronal protection from anoxic and ischemic damage. Amino Acids 23(1\u20133):221\u2013229. doi: 10.1007\/s00726-001-0133-3","journal-title":"Amino Acids"},{"issue":"5","key":"2165_CR8","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s00726-011-0851-0","volume":"40","author":"MF Beal","year":"2011","unstructured":"Beal MF (2011) Neuroprotective effects of creatine. Amino Acids 40(5):1305\u20131313. doi: 10.1007\/s00726-011-0851-0","journal-title":"Amino Acids"},{"issue":"10","key":"2165_CR9","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1523\/JNEUROSCI.13-10-04181.1993","volume":"13","author":"MF Beal","year":"1993","unstructured":"Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, Hyman BT (1993) Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 13(10):4181\u20134192","journal-title":"J Neurosci"},{"issue":"1","key":"2165_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00415-005-0595-4","volume":"252","author":"A Bender","year":"2005","unstructured":"Bender A, Auer DP, Merl T, Reilmann R, Saemann P, Yassouridis A, Bender J, Weindl A, Dose M, Gasser T, Klopstock T (2005) Creatine supplementation lowers brain glutamate levels in Huntington\u2019s disease. J Neurol 252(1):36\u201341. doi: 10.1007\/s00415-005-0595-4","journal-title":"J Neurol"},{"issue":"7","key":"2165_CR11","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1212\/01.wnl.0000238518.34389.12","volume":"67","author":"A Bender","year":"2006","unstructured":"Bender A, Koch W, Elstner M, Schombacher Y, Bender J, Moeschl M, Gekeler F, Muller-Myhsok B, Gasser T, Tatsch K, Klopstock T (2006) Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology 67(7):1262\u20131264","journal-title":"Neurology"},{"issue":"3","key":"2165_CR12","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.nutres.2008.01.001","volume":"28","author":"A Bender","year":"2008","unstructured":"Bender A, Samtleben W, Elstner M, Klopstock T (2008) Long-term creatine supplementation is safe in aged patients with Parkinson disease. Nutr Res 28(3):172\u2013178. doi: 10.1016\/j.nutres.2008.01.001","journal-title":"Nutr Res"},{"issue":"7","key":"2165_CR13","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1017\/S0007114510004733","volume":"105","author":"D Benton","year":"2011","unstructured":"Benton D, Donohoe R (2011) The influence of creatine supplementation on the cognitive functioning of vegetarians and omnivores. Br J Nutr 105(7):1100\u20131105. doi: 10.1017\/S0007114510004733","journal-title":"Br J Nutr"},{"issue":"1","key":"2165_CR14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00441-004-0956-9","volume":"318","author":"H Braak","year":"2004","unstructured":"Braak H, Ghebremedhin E, R\u00fcb U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson\u2019s disease-related pathology. Cell Tissue Res 318(1):121\u2013134","journal-title":"Cell Tissue Res"},{"issue":"1\u20132","key":"2165_CR15","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0169-328X(00)00269-2","volume":"86","author":"O Braissant","year":"2001","unstructured":"Braissant O, Henry H, Loup M, Eilers B, Bachmann C (2001) Endogenous synthesis and transport of creatine in the rat brain: an in situ hybridization study. Brain Res Mol Brain Res 86(1\u20132):193\u2013201","journal-title":"Brain Res Mol Brain Res"},{"issue":"13","key":"2165_CR16","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1212\/01.wnl.0000277530.05450.ff","volume":"69","author":"BJ Brew","year":"2007","unstructured":"Brew BJ (2007) Lost in translation: again, another failed neuroprotection trial. Neurology 69(13):1308\u20131309. doi: 10.1212\/01.wnl.0000277530.05450.ff","journal-title":"Neurology"},{"issue":"11","key":"2165_CR17","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/35097565","volume":"2","author":"DW Cleveland","year":"2001","unstructured":"Cleveland DW, Rothstein JD (2001) From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2(11):806\u2013819. doi: 10.1038\/35097565","journal-title":"Nat Rev Neurosci"},{"issue":"5820","key":"2165_CR18","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1126\/science.315.5820.1778","volume":"315","author":"J Couzin","year":"2007","unstructured":"Couzin J (2007) Clinical research. Testing a novel strategy against Parkinson\u2019s disease. Science 315(5820):1778","journal-title":"Science"},{"issue":"6","key":"2165_CR19","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1046\/j.1471-4159.2003.01706.x","volume":"85","author":"A Dedeoglu","year":"2003","unstructured":"Dedeoglu A, Kubilus JK, Yang L, Ferrante KL, Hersch SM, Beal MF, Ferrante RJ (2003) Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington\u2019s disease transgenic mice. J Neurochem 85(6):1359\u20131367","journal-title":"J Neurochem"},{"issue":"1","key":"2165_CR20","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.coph.2012.08.005","volume":"13","author":"C Ergorul","year":"2013","unstructured":"Ergorul C, Levin LA (2013) Solving the lost in translation problem: improving the effectiveness of translational research. Curr Opin Pharmacol 13(1):108\u2013114. doi: 10.1016\/j.coph.2012.08.005","journal-title":"Curr Opin Pharmacol"},{"issue":"12","key":"2165_CR21","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1523\/JNEUROSCI.20-12-04389.2000","volume":"20","author":"RJ Ferrante","year":"2000","unstructured":"Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK, Kaddurah-Daouk R, Hersch SM, Beal MF (2000) Neuroprotective effects of creatine in a transgenic mouse model of Huntington\u2019s disease. J Neurosci 20(12):4389\u20134397","journal-title":"J Neurosci"},{"issue":"2","key":"2165_CR22","doi-asserted-by":"publisher","first-page":"e30554","DOI":"10.1371\/journal.pone.0030554","volume":"7","author":"J Genius","year":"2012","unstructured":"Genius J, Geiger J, Bender A, Moller HJ, Klopstock T, Rujescu D (2012) Creatine protects against excitoxicity in an in vitro model of neurodegeneration. PLoS One 7(2):e30554. doi: 10.1371\/journal.pone.0030554","journal-title":"PLoS One"},{"issue":"4","key":"2165_CR23","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/ana.10554","volume":"53","author":"GJ Groeneveld","year":"2003","unstructured":"Groeneveld GJ, Veldink JH, van der Tweel I, Kalmijn S, Beijer C, de Visser M, Wokke JH, Franssen H, van den Berg LH (2003) A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 53(4):437\u2013445. doi: 10.1002\/ana.10554","journal-title":"Ann Neurol"},{"issue":"2","key":"2165_CR24","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00726-011-1132-7","volume":"43","author":"B Gualano","year":"2012","unstructured":"Gualano B, Roschel H, Lancha-Jr AH, Brightbill CE, Rawson ES (2012) In sickness and in health: the widespread application of creatine supplementation. Amino Acids 43(2):519\u2013529. doi: 10.1007\/s00726-011-1132-7","journal-title":"Amino Acids"},{"issue":"5166","key":"2165_CR25","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1126\/science.8209258","volume":"264","author":"ME Gurney","year":"1994","unstructured":"Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX et al (1994) Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 264(5166):1772\u20131775","journal-title":"Science"},{"issue":"3\u20135","key":"2165_CR26","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000111342","volume":"15","author":"W Hemmer","year":"1993","unstructured":"Hemmer W, Wallimann T (1993) Functional aspects of creatine kinase in brain. Dev Neurosci 15(3\u20135):249\u2013260","journal-title":"Dev Neurosci"},{"issue":"2","key":"2165_CR27","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1212\/01.wnl.0000194318.74946.b6","volume":"66","author":"SM Hersch","year":"2006","unstructured":"Hersch SM, Gevorkian S, Marder K, Moskowitz C, Feigin A, Cox M, Como P, Zimmerman C, Lin M, Zhang L, Ulug AM, Beal MF, Matson W, Bogdanov M, Ebbel E, Zaleta A, Kaneko Y, Jenkins B, Hevelone N, Zhang H, Yu H, Schoenfeld D, Ferrante R, Rosas HD (2006) Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2\u2032dG. Neurology 66(2):250\u2013252. doi: 10.1212\/01.wnl.0000194318.74946.b6","journal-title":"Neurology"},{"issue":"5","key":"2165_CR28","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/mus.20489","volume":"33","author":"I Hervias","year":"2006","unstructured":"Hervias I, Beal MF, Manfredi G (2006) Mitochondrial dysfunction and amyotrophic lateral sclerosis. Muscle Nerve 33(5):598\u2013608. doi: 10.1002\/mus.20489","journal-title":"Muscle Nerve"},{"issue":"6","key":"2165_CR29","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1001\/jama.2015.120","volume":"313","author":"K Kieburtz","year":"2015","unstructured":"Kieburtz K, Tilley BC, Elm JJ, Babcock D, Hauser R, Ross GW, Augustine AH, Augustine EU, Aminoff MJ, Bodis-Wollner IG, Boyd J, Cambi F, Chou K, Christine CW, Cines M, Dahodwala N, Derwent L, Dewey RB Jr, Hawthorne K, Houghton DJ, Kamp C, Leehey M, Lew MF, Liang GS, Luo ST, Mari Z, Morgan JC, Parashos S, Perez A, Petrovitch H, Rajan S, Reichwein S, Roth JT, Schneider JS, Shannon KM, Simon DK, Simuni T, Singer C, Sudarsky L, Tanner CM, Umeh CC, Williams K, Wills AM (2015) Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA 313(6):584\u2013593. doi: 10.1001\/jama.2015.120","journal-title":"JAMA"},{"issue":"20","key":"2165_CR30","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.1093\/hmg\/ddq306","volume":"19","author":"J Kim","year":"2010","unstructured":"Kim J, Moody JP, Edgerly CK, Bordiuk OL, Cormier K, Smith K, Beal MF, Ferrante RJ (2010) Mitochondrial loss, dysfunction and altered dynamics in Huntington\u2032s disease. Hum Mol Genet 19(20):3919\u20133935. doi: 10.1093\/hmg\/ddq306","journal-title":"Hum Mol Genet"},{"issue":"3","key":"2165_CR31","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/6568","volume":"5","author":"P Klivenyi","year":"1999","unstructured":"Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA, Mueller G, Wermer M, Kaddurah-Daouk R, Beal MF (1999) Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 5(3):347\u2013350","journal-title":"Nat Med"},{"issue":"3","key":"2165_CR32","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1385\/JMN:21:3:191","volume":"21","author":"P Klivenyi","year":"2003","unstructured":"Klivenyi P, Gardian G, Calingasan NY, Yang L, Beal MF (2003) Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) mouse model of Parkinson\u2019s disease. J Mol Neurosci 21(3):191\u2013198","journal-title":"J Mol Neurosci"},{"issue":"3","key":"2165_CR33","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1046\/j.1471-4159.2003.02160.x","volume":"88","author":"P Klivenyi","year":"2004","unstructured":"Klivenyi P, Kiaei M, Gardian G, Calingasan NY, Beal MF (2004) Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem 88(3):576\u2013582","journal-title":"J Neurochem"},{"issue":"5","key":"2165_CR34","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s00726-011-0850-1","volume":"40","author":"T Klopstock","year":"2011","unstructured":"Klopstock T, Elstner M, Bender A (2011) Creatine in mouse models of neurodegeneration and aging. Amino Acids 40(5):1297\u20131303. doi: 10.1007\/s00726-011-0850-1","journal-title":"Amino Acids"},{"issue":"1","key":"2165_CR35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1006\/bbrc.2001.6164","volume":"290","author":"JM Lawler","year":"2002","unstructured":"Lawler JM, Barnes WS, Wu G, Song W, Demaree S (2002) Direct antioxidant properties of creatine. Biochem Biophys Res Commun 290(1):47\u201352. doi: 10.1006\/bbrc.2001.6164","journal-title":"Biochem Biophys Res Commun"},{"issue":"3\u20134","key":"2165_CR36","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000377676","volume":"73","author":"Z Li","year":"2015","unstructured":"Li Z, Wang P, Yu Z, Cong Y, Sun H, Zhang J, Zhang J, Sun C, Zhang Y, Ju X (2015) The effect of creatine and coenzyme q10 combination therapy on mild cognitive impairment in Parkinson\u2019s disease. Eur Neurol 73(3\u20134):205\u2013211. doi: 10.1159\/000377676","journal-title":"Eur Neurol"},{"issue":"1","key":"2165_CR37","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/1531-8249(200007)48:1<72::AID-ANA11>3.0.CO;2-I","volume":"48","author":"R Lodi","year":"2000","unstructured":"Lodi R, Schapira AH, Manners D, Styles P, Wood NW, Taylor DJ, Warner TT (2000) Abnormal in vivo skeletal muscle energy metabolism in Huntington\u2019s disease and dentatorubropallidoluysian atrophy. Ann Neurol 48(1):72\u201376","journal-title":"Ann Neurol"},{"issue":"5","key":"2165_CR38","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/cne.23667","volume":"523","author":"MT Lowe","year":"2015","unstructured":"Lowe MT, Faull RL, Christie DL, Waldvogel HJ (2015) Distribution of the creatine transporter throughout the human brain reveals a spectrum of creatine transporter immunoreactivity. J Comp Neurol 523(5):699\u2013725. doi: 10.1002\/cne.23667","journal-title":"J Comp Neurol"},{"issue":"2","key":"2165_CR39","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0925-4927(03)00046-5","volume":"123","author":"IK Lyoo","year":"2003","unstructured":"Lyoo IK, Kong SW, Sung SM, Hirashima F, Parow A, Hennen J, Cohen BM, Renshaw PF (2003) Multinuclear magnetic resonance spectroscopy of high-energy phosphate metabolites in human brain following oral supplementation of creatine-monohydrate. Psychiatry Res 123(2):87\u2013100","journal-title":"Psychiatry Res"},{"issue":"2","key":"2165_CR40","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.neuroscience.2009.06.065","volume":"163","author":"CS Mak","year":"2009","unstructured":"Mak CS, Waldvogel HJ, Dodd JR, Gilbert RT, Lowe MT, Birch NP, Faull RL, Christie DL (2009) Immunohistochemical localisation of the creatine transporter in the rat brain. Neuroscience 163(2):571\u2013585. doi: 10.1016\/j.neuroscience.2009.06.065","journal-title":"Neuroscience"},{"issue":"1","key":"2165_CR41","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1523\/JNEUROSCI.18-01-00156.1998","volume":"18","author":"RT Matthews","year":"1998","unstructured":"Matthews RT, Yang L, Jenkins BG, Ferrante RJ, Rosen BR, Kaddurah-Daouk R, Beal MF (1998) Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington\u2019s disease. J Neurosci 18(1):156\u2013163","journal-title":"J Neurosci"},{"issue":"1","key":"2165_CR42","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1006\/exnr.1999.7049","volume":"157","author":"RT Matthews","year":"1999","unstructured":"Matthews RT, Ferrante RJ, Klivenyi P, Yang L, Klein AM, Mueller G, Kaddurah-Daouk R, Beal MF (1999) Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol 157(1):142\u2013149. doi: 10.1006\/exnr.1999.7049","journal-title":"Exp Neurol"},{"key":"2165_CR43","unstructured":"National Academies of Sciences, Engineering, and Medicine (2015) Reproducibility issues in research with animals and animal models: workshop in Brief. The National Academies Press, Washington, DC, 1\u20138. ISBN 978-0-309-38017-1"},{"issue":"5","key":"2165_CR44","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1212\/01.wnl.0000201252.57661.e1","volume":"66","author":"NINDS NET-PD Investigators","year":"2006","unstructured":"NINDS NET-PD Investigators (2006) A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66(5):664\u2013671","journal-title":"Neurology"},{"issue":"2","key":"2165_CR45","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0014-5793(97)01045-4","volume":"414","author":"E O\u2019Gorman","year":"1997","unstructured":"O\u2019Gorman E, Beutner G, Dolder M, Koretsky AP, Brdiczka D, Wallimann T (1997) The role of creatine kinase in inhibition of mitochondrial permeability transition. FEBS Lett 414(2):253\u2013257","journal-title":"FEBS Lett"},{"issue":"Suppl 17","key":"2165_CR46","doi-asserted-by":"crossref","first-page":"S335","DOI":"10.1002\/mds.21675","volume":"22","author":"CW Olanow","year":"2007","unstructured":"Olanow CW (2007) The pathogenesis of cell death in Parkinson\u2019s disease\u20142007. Mov Disord 22(Suppl 17):S335\u2013S342","journal-title":"Mov Disord"},{"key":"2165_CR47","doi-asserted-by":"publisher","first-page":"CD005225","DOI":"10.1002\/14651858.CD005225.pub3","volume":"12","author":"DM Pastula","year":"2012","unstructured":"Pastula DM, Moore DH, Bedlack RS (2012) Creatine for amyotrophic lateral sclerosis\/motor neuron disease. Cochrane Database Syst Rev 12:CD005225. doi: 10.1002\/14651858.CD005225.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"1\u20132","key":"2165_CR48","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0006-8993(03)02547-2","volume":"974","author":"L Perasso","year":"2003","unstructured":"Perasso L, Cupello A, Lunardi GL, Principato C, Gandolfo C, Balestrino M (2003) Kinetics of creatine in blood and brain after intraperitoneal injection in the rat. Brain Res 974(1\u20132):37\u201342","journal-title":"Brain Res"},{"issue":"5","key":"2165_CR49","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s11064-007-9492-9","volume":"33","author":"L Perasso","year":"2008","unstructured":"Perasso L, Lunardi G, Risso F, Pohvozcheva A, Leko M, Gandolfo C, Florio T, Cupello A, Burov S, Balestrino M (2008) Protective effects of some creatine derivatives in brain tissue anoxia. Neurochem Res 33(5):765\u2013775","journal-title":"Neurochem Res"},{"key":"2165_CR50","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.brainres.2009.06.009","volume":"1285","author":"L Perasso","year":"2009","unstructured":"Perasso L, Adriano E, Ruggeri P, Burov SV, Gandolfo C, Balestrino M (2009) In vivo neuroprotection by a creatine-derived compound: phosphocreatine-Mg-complex acetate. Brain Res 1285:158\u2013163","journal-title":"Brain Res"},{"issue":"2","key":"2165_CR51","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/med.20255","volume":"33","author":"L Perasso","year":"2013","unstructured":"Perasso L, Spallarossa P, Gandolfo C, Ruggeri P, Balestrino M (2013) Therapeutic use of creatine in brain or heart ischemia: available data and future perspectives. Med Res Rev 33(2):336\u2013363. doi: 10.1002\/med.20255","journal-title":"Med Res Rev"},{"issue":"5","key":"2165_CR52","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1172\/JCI71601","volume":"125","author":"OM Peters","year":"2015","unstructured":"Peters OM, Ghasemi M, Brown RH Jr (2015) Emerging mechanisms of molecular pathology in ALS. J Clin Invest 125(5):1767\u20131779. doi: 10.1172\/JCI71601","journal-title":"J Clin Invest"},{"issue":"3","key":"2165_CR53","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/00007256-200030030-00002","volume":"30","author":"JR Poortmans","year":"2000","unstructured":"Poortmans JR, Francaux M (2000) Adverse effects of creatine supplementation: fact or fiction? Sports Med 30(3):155\u2013170","journal-title":"Sports Med"},{"issue":"10","key":"2165_CR54","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1212\/wnl.0000000000000187","volume":"82","author":"HD Rosas","year":"2014","unstructured":"Rosas HD, Doros G, Gevorkian S, Malarick K, Reuter M, Coutu JP, Triggs TD, Wilkens PJ, Matson W, Salat DH, Hersch SM (2014) Precrest: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease. Neurology 82(10):850\u2013857. doi: 10.1212\/wnl.0000000000000187","journal-title":"Neurology"},{"issue":"5","key":"2165_CR55","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1080\/17482960802028890","volume":"9","author":"J Rosenfeld","year":"2008","unstructured":"Rosenfeld J, King RM, Jackson CE, Bedlack RS, Barohn RJ, Dick A, Phillips LH, Chapin J, Gelinas DF, Lou JS (2008) Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS. Amyotroph Lateral Scler 9(5):266\u2013272. doi: 10.1080\/17482960802028890","journal-title":"Amyotroph Lateral Scler"},{"issue":"1","key":"2165_CR001","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1474-4422(07)70327-7","volume":"7","author":"AH Schapira","year":"2008","unstructured":"Schapira AH (2008) Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 7(1):97\u2013109","journal-title":"Lancet Neurol"},{"issue":"1","key":"2165_CR56","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1080\/17482960701856300","volume":"9","author":"S Scott","year":"2008","unstructured":"Scott S, Kranz JE, Cole J, Lincecum JM, Thompson K, Kelly N, Bostrom A, Theodoss J, Al-Nakhala BM, Vieira FG, Ramasubbu J, Heywood JA (2008) Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler 9(1):4\u201315. doi: 10.1080\/17482960701856300","journal-title":"Amyotroph Lateral Scler"},{"issue":"9","key":"2165_CR57","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1212\/01.WNL.0000142992.81995.F0","volume":"63","author":"JM Shefner","year":"2004","unstructured":"Shefner JM, Cudkowicz ME, Schoenfeld D, Conrad T, Taft J, Chilton M, Urbinelli L, Qureshi M, Zhang H, Pestronk A, Caress J, Donofrio P, Sorenson E, Bradley W, Lomen-Hoerth C, Pioro E, Rezania K, Ross M, Pascuzzi R, Heiman-Patterson T, Tandan R, Mitsumoto H, Rothstein J, Smith-Palmer T, MacDonald D, Burke D, NEALS Consortium (2004) A clinical trial of creatine in ALS. Neurology 63(9):1656\u20131661","journal-title":"Neurology"},{"key":"2165_CR58","doi-asserted-by":"publisher","first-page":"222","DOI":"10.12688\/f1000research.5218.1","volume":"3","author":"RN Smith","year":"2014","unstructured":"Smith RN, Agharkar AS, Gonzales EB (2014) A review of creatine supplementation in age-related diseases: more than a supplement for athletes. F1000Res 3:222. doi: 10.12688\/f1000research.5218.1","journal-title":"F1000Res"},{"issue":"3","key":"2165_CR59","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0306-4522(03)00212-4","volume":"119","author":"RJ Snow","year":"2003","unstructured":"Snow RJ, Turnbull J, da Silva S, Jiang F, Tarnopolsky MA (2003) Creatine supplementation and riluzole treatment provide similar beneficial effects in copper, zinc superoxide dismutase (G93A) transgenic mice. Neuroscience 119(3):661\u2013667","journal-title":"Neuroscience"},{"issue":"6","key":"2165_CR60","doi-asserted-by":"crossref","first-page":"378","DOI":"10.2174\/1570162X13666150121101544","volume":"12","author":"PR Stevens","year":"2014","unstructured":"Stevens PR, Gawryluk JW, Hui L, Chen X, Geiger JD (2014) Creatine protects against mitochondrial dysfunction associated with HIV-1 Tat-induced neuronal injury. Curr HIV Res 12(6):378\u2013387","journal-title":"Curr HIV Res"},{"issue":"1","key":"2165_CR61","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/1531-8249(199901)45:1<25::AID-ART6>3.0.CO;2-E","volume":"45","author":"SJ Tabrizi","year":"1999","unstructured":"Tabrizi SJ, Cleeter MW, Xuereb J, Taanman JW, Cooper JM, Schapira AH (1999) Biochemical abnormalities and excitotoxicity in Huntington\u2019s disease brain. Ann Neurol 45(1):25\u201332","journal-title":"Ann Neurol"},{"issue":"Suppl 2","key":"2165_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000322696","volume":"57","author":"MA Tarnopolsky","year":"2010","unstructured":"Tarnopolsky MA (2010) Caffeine and creatine use in sport. Ann Nutr Metab 57(Suppl 2):1\u20138. doi: 10.1159\/000322696","journal-title":"Ann Nutr Metab"},{"issue":"4","key":"2165_CR63","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1053\/j.jrn.2006.04.025","volume":"16","author":"B Thorsteinsdottir","year":"2006","unstructured":"Thorsteinsdottir B, Grande JP, Garovic VD (2006) Acute renal failure in a young weight lifter taking multiple food supplements, including creatine monohydrate. J Ren Nutr 16(4):341\u2013345. doi: 10.1053\/j.jrn.2006.04.025","journal-title":"J Ren Nutr"},{"issue":"4","key":"2165_CR64","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1523\/jneurosci.3113-14.2015","volume":"35","author":"CE Turner","year":"2015","unstructured":"Turner CE, Byblow WD, Gant N (2015) Creatine supplementation enhances corticomotor excitability and cognitive performance during oxygen deprivation. J Neurosci 35(4):1773\u20131780. doi: 10.1523\/jneurosci.3113-14.2015","journal-title":"J Neurosci"},{"issue":"7","key":"2165_CR65","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1212\/01.WNL.0000090629.40891.4B","volume":"61","author":"P Verbessem","year":"2003","unstructured":"Verbessem P, Lemiere J, Eijnde BO, Swinnen S, Vanhees L, Van Leemputte M, Hespel P, Dom R (2003) Creatine supplementation in Huntington\u2019s disease: a placebo-controlled pilot trial. Neurology 61(7):925\u2013930","journal-title":"Neurology"},{"issue":"5","key":"2165_CR66","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00726-011-0877-3","volume":"40","author":"T Wallimann","year":"2011","unstructured":"Wallimann T, Tokarska-Schlattner M, Schlattner U (2011) The creatine kinase system and pleiotropic effects of creatine. Amino Acids 40(5):1271\u20131296. doi: 10.1007\/s00726-011-0877-3","journal-title":"Amino Acids"},{"issue":"6","key":"2165_CR67","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/0896-6273(95)90259-7","volume":"14","author":"PC Wong","year":"1995","unstructured":"Wong PC, Pardo CA, Borchelt DR, Lee MK, Copeland NG, Jenkins NA, Sisodia SS, Cleveland DW, Price DL (1995) An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14(6):1105\u20131116","journal-title":"Neuron"},{"key":"2165_CR68","doi-asserted-by":"publisher","first-page":"CD009646","DOI":"10.1111\/j.1471-4159.2009.06074.x","volume":"6","author":"Y Xiao","year":"2014","unstructured":"Xiao Y, Luo M, Luo H, Wan J (2014) Creatine for Parkinson\u2019s disease. Cochrane Database Syst Rev 6:CD009646. doi: 10.1111\/j.1471-4159.2009.06074.x","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"2165_CR69","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1111\/j.1471-4159.2009.06074.x","volume":"109","author":"L Yang","year":"2009","unstructured":"Yang L, Calingasan NY, Wille EJ, Cormier K, Smith K, Ferrante RJ, Beal MF (2009) Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson\u2019s and Huntington\u2019s diseases. J Neurochem 109(5):1427\u20131439. doi: 10.1111\/j.1471-4159.2009.06074.x","journal-title":"J Neurochem"},{"issue":"7","key":"2165_CR70","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1017\/S0007114513003802","volume":"111","author":"M Yazigi Solis","year":"2014","unstructured":"Yazigi Solis M, de Salles Painelli V, Giannini Artioli G, Roschel H, Concepci\u00f3n Otaduy M, Gualano B (2014) Brain creatine depletion in vegetarians? A cross-sectional \u00b9H-magnetic resonance spectroscopy (\u00b9H-MRS) study. Br J Nutr 111(7):1272\u20131274. doi: 10.1017\/S0007114513003802","journal-title":"Br J Nutr"},{"issue":"2","key":"2165_CR71","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/ana.10476","volume":"53","author":"W Zhang","year":"2003","unstructured":"Zhang W, Narayanan M, Friedlander RM (2003) Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol 53(2):267\u2013270. doi: 10.1002\/ana.10476","journal-title":"Ann Neurol"}],"container-title":["Amino Acids"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00726-015-2165-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00726-015-2165-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00726-015-2165-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T09:42:21Z","timestamp":1567503741000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00726-015-2165-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,9]]},"references-count":72,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["2165"],"URL":"https:\/\/doi.org\/10.1007\/s00726-015-2165-0","relation":{},"ISSN":["0939-4451","1438-2199"],"issn-type":[{"value":"0939-4451","type":"print"},{"value":"1438-2199","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,9]]}}}